Business
Annual General Meeting Statement
Proteome Sciences plc reported at its Annual General Meeting that its services business is experiencing good order levels and a recovery in TMT and reagent sales in the first half of the year, following budget cuts in 2025. The company believes its significant investment over the past two years positions it well to achieve substantial returns in the growing proteomics field. Disclaimer*
About this update from Proteome Sciences Plc
14 May 2026 Proteome Sciences plc ("Proteome Sciences" or the "Company") Annual General Meeting Statement At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, made the following statement: "Good progress is being made in order levels in our services business and the recovery that we hoped for in TMT and reagent sales continues in the first half following the cuts in US NIH budgets and academic grants in 2025. With the significant investment made in the business over the last 2 years, we believe we are well positioned to deliver substantial returns from our activities in the fast growing field of proteomics." - Ends - For further information: Proteome Sciences plc Christopher Pearce, Executive Chairman Dr. Ian Pike, Chief Scientific Officer Tel: +44 (0)20 7043 2116 Richard Dennis, Chief Commercial Officer SP Angel Corporate Finance LLP (Nominated Adviser & Broker) David Hignell/Richard Morrison/Josh Ray (Corporate Finance) Vadim Alexandre (Corporate Broking) Tel: +44 (0) 20 3470 0470 About Proteome Sciences plc. (www.proteomics.com) Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the selectivity that drugs have to binding one or more proteins in the sample proteome. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available. Further information on the Company can be found on its website at: https://www.proteomics.com/ The Company's LEI is 213800Q62ICXANKU2986. This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and ...
View stock analysis, news, and events for Proteome Sciences Plc